ARRAY BIOPHARMA INC's ticker is ARRY and the CUSIP is 04269X105. A total of 196 filers reported holding ARRAY BIOPHARMA INC in Q1 2017. The put-call ratio across all filers is 0.57 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $36,865,000 | +41.9% | 795,712 | -25.3% | 0.68% | +35.6% |
| Q1 2019 | $25,982,000 | +9.8% | 1,065,712 | -35.8% | 0.50% | +5.5% |
| Q4 2018 | $23,664,000 | -45.3% | 1,660,631 | -41.7% | 0.48% | -10.3% |
| Q3 2018 | $43,260,000 | +159.6% | 2,846,000 | +186.6% | 0.53% | +62.7% |
| Q2 2018 | $16,663,000 | -53.7% | 993,000 | -55.0% | 0.33% | -12.8% |
| Q1 2018 | $36,002,000 | +172.3% | 2,206,000 | +113.6% | 0.38% | +138.9% |
| Q4 2017 | $13,222,000 | +89.3% | 1,033,000 | +81.9% | 0.16% | +78.4% |
| Q3 2017 | $6,986,000 | +73.9% | 568,000 | +18.3% | 0.09% | -13.7% |
| Q2 2017 | $4,018,000 | +164.3% | 480,000 | +182.4% | 0.10% | +142.9% |
| Q1 2017 | $1,520,000 | -3.9% | 170,000 | -5.6% | 0.04% | -12.5% |
| Q4 2016 | $1,582,000 | +80.2% | 180,000 | +38.5% | 0.05% | +84.6% |
| Q3 2016 | $878,000 | – | 130,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Redmile Group, LLC | 16,618,776 | $146,079,000 | 12.59% |
| BVF INC/IL | 4,986,186 | $43,829,000 | 8.81% |
| First Light Asset Management, LLC | 1,000,361 | $8,793,000 | 3.86% |
| Crosspoint Capital Strategies, LLC | 463,005 | $4,070,000 | 3.62% |
| Consonance Capital Management LP | 2,723,471 | $23,912,000 | 2.63% |
| KOPP INVESTMENT ADVISORS LLC | 219,926 | $1,933,000 | 2.04% |
| SPHERA FUNDS MANAGEMENT LTD. | 900,000 | $7,911,000 | 2.00% |
| Orbimed Advisors | 16,088,800 | $141,421,000 | 1.80% |
| Cormorant Asset Management, LP | 1,150,000 | $10,109,000 | 1.36% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 2,073,680 | $18,227,000 | 1.26% |